Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma
Andres Quesada(The University of Texas MD Anderson Cancer Center), Shaoying Li(Third Affiliated Hospital of Guangzhou Medical University), Parth Desai(The University of Texas MD Anderson Cancer Center), Adam C. Seegmiller(Vanderbilt University Medical Center), C. Cameron Yin(Chinese Academy of Agricultural Sciences), Peng Wei(Creighton University), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Huda M Hawsawi(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Nishitha Reddy(Vanderbilt University), Wei Wang(The University of Texas MD Anderson Cancer Center), Pei Lin(The University of Texas MD Anderson Cancer Center), Zhuang Zuo(The University of Texas MD Anderson Cancer Center), Jie Xu(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries)
Cited by 53
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782